Biodegradable artery graft could revolutionize leg bypass surgery

NCT ID NCT07716020

Not yet recruiting Disease control Sponsor: Xeltis Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study tests a new type of bypass graft made from a biodegradable polymer for people with peripheral artery disease who need leg bypass surgery. The graft is designed to restore blood flow and then gradually be replaced by the body's own tissue. The trial will enroll 15 participants across Europe to see if the graft is safe and works as intended.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a biodegradable polymer vascular conduit called the XPAD bypass conduit
What this could lead to: If successful, this could provide a new option for bypass surgery that restores blood flow and may reduce complications compared to synthetic grafts.
What could go wrong: This is a small, early feasibility study with only 15 participants, so results may not apply broadly. The conduit could fail to stay open or cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIPHERAL ARTERIAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

peripheral arterial disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PERIPHERAL ARTERIAL DISEASE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.